{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:29:13Z","timestamp":1761182953959,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jiac.2019.10.008","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T14:17:01Z","timestamp":1573222621000},"page":"289-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Desensitization to trimethoprim-sulfamethoxazole in a toxoplasmic encephalitis patient who was intolerant to conventional treatments"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7271-1774","authenticated-orcid":false,"given":"Nobuyuki","family":"Miyata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Hikosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Norose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuo","family":"Tachikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2019.10.008_bib1","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","article-title":"Toxoplasmosis","volume":"363","author":"Montoya","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2019.10.008_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/157.1.1","article-title":"AIDS commentary. toxoplasmic encephalitis","volume":"157","author":"Luft","year":"1988","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jiac.2019.10.008_bib3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1179\/2047773213Y.0000000094","article-title":"Antibiotics for human toxoplasmosis: a systematic review of randomized trials","volume":"107","author":"Rajapakse","year":"2013","journal-title":"Pathog Glob Health"},{"key":"10.1016\/j.jiac.2019.10.008_bib4","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1128\/AAC.42.6.1346","article-title":"Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian collaborative study group","volume":"42","author":"Torre","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.10.008_bib5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/0002-9343(87)90151-3","article-title":"Assessment of therapy for toxoplasma encephalitis. the TE study group","volume":"82","author":"Haverkos","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.jiac.2019.10.008_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-116-1-33","article-title":"Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. the California collaborative treatment group","volume":"116","author":"Dannemann","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jiac.2019.10.008_bib7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0091-6749(94)70048-6","article-title":"Desensitization to trimethoprim\/sulfamethoxazole in HIV-infected patients","volume":"93","author":"Absar","year":"1994","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jiac.2019.10.008_bib8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/clinids\/20.4.849","article-title":"Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ","volume":"20","author":"Gluckstein","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2019.10.008_bib9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00002030-199506000-00007","article-title":"Two-day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients","volume":"9","author":"Nguyen","year":"1995","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2019.10.008_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1081-1206(10)63034-7","article-title":"Trimethoprim\/sulfamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons","volume":"79","author":"Rich","year":"1997","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jiac.2019.10.008_bib11","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0091-6749(98)70343-4","article-title":"Six-hour trimethoprim-sulfamethoxazole-graded challenge in HIV-infected patients","volume":"102","author":"Demoly","year":"1998","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jiac.2019.10.008_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1081-1206(10)62474-X","article-title":"A\u00a05-day course of oral desensitization to trimethoprim\/sulfamethoxazole (T\/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T\/S","volume":"85","author":"Yoshizawa","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jiac.2019.10.008_bib13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00042560-200008010-00007","article-title":"Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS clinical trials group 268","volume":"24","author":"Para","year":"2000","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2019.10.008_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00002030-199503000-00013","article-title":"Trimethoprim-sulphamethoxazole desensitization in HIV-infected patients: an open study","volume":"9","author":"Bachmeyer","year":"1995","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2019.10.008_bib15","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1081-1206(10)63338-8","article-title":"Successful oral desensitization to trimethoprim-sulfamethoxazole in acquired immune deficiency syndrome","volume":"77","author":"Kalanadhabhatta","year":"1996","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jiac.2019.10.008_bib16","first-page":"177","article-title":"Desensitization to trimethoprim sulfamethoxazole in patients with acquired immune deficiency syndrome and Pneumocystis carinii pneumonia","volume":"62","author":"White","year":"1989","journal-title":"Ann Allergy"},{"key":"10.1016\/j.jiac.2019.10.008_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0014-4894(92)90149-5","article-title":"Toxoplasma gondii: characterization of a mutant resistant to sulfonamides","volume":"74","author":"Pfefferkorn","year":"1992","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.jiac.2019.10.008_bib18","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1086\/340577","article-title":"The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis","volume":"185","author":"Aspinall","year":"2002","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jiac.2019.10.008_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1051\/parasite\/2013020","article-title":"Sulfadiazine resistance in Toxoplasma gondii: no involvement of overexpression or polymorphisms in genes of therapeutic targets and ABC transporters","volume":"20","author":"Doliwa","year":"2013","journal-title":"Parasite"},{"key":"10.1016\/j.jiac.2019.10.008_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/1545109707301244","article-title":"Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients","volume":"7","author":"Kongsaengdao","year":"2008","journal-title":"J\u00a0Int Assoc Physicians AIDS Care (Chic)"},{"key":"10.1016\/j.jiac.2019.10.008_bib21","first-page":"956","article-title":"Treating AIDS-associated cerebral toxoplasmosis-pyrimethamine plus sulfadiazine compared with cotrimoxazole, and outcome with adjunctive glucocorticoids","volume":"97","author":"Arens","year":"2007","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.jiac.2019.10.008_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/jac\/36.2.435","article-title":"Marked variation in pyrimethamine disposition in AIDS patients treated for cerebral toxoplasmosis","volume":"36","author":"Winstanley","year":"1995","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2019.10.008_bib23","first-page":"1","article-title":"Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the national institutes of health, and the HIV medicine association\/infectious diseases society of America","volume":"53","author":"Benson","year":"2004","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"key":"10.1016\/j.jiac.2019.10.008_bib24","doi-asserted-by":"crossref","first-page":"e0138204","DOI":"10.1371\/journal.pone.0138204","article-title":"A\u00a0systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans","volume":"10","author":"Wei","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2019.10.008_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1365-2036.1998.00309.x","article-title":"Review article: glycyrrhizin as a potential treatment for chronic hepatitis C","volume":"12","author":"van Rossum","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jiac.2019.10.008_bib26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2119\/molmed.2013.00099","article-title":"Emerging role of high-mobility group box 1 (HMGB1) in liver diseases","volume":"19","author":"Chen","year":"2013","journal-title":"Mol Med"},{"key":"10.1016\/j.jiac.2019.10.008_bib27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2796.2003.01302.x","article-title":"Extracellular role of HMGB1 in inflammation and sepsis","volume":"255","author":"Wang","year":"2004","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jiac.2019.10.008_bib28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.chembiol.2007.03.007","article-title":"Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities","volume":"14","author":"Mollica","year":"2007","journal-title":"Chem Biol"},{"key":"10.1016\/j.jiac.2019.10.008_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7326\/0003-4819-100-4-495","article-title":"Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome","volume":"100","author":"Gordin","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jiac.2019.10.008_bib30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1081-1206(10)60037-3","article-title":"Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection","volume":"76","author":"Belchi-Hernandez","year":"1996","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X19303083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X19303083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:59:16Z","timestamp":1761159556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X19303083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1341321X19303083"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2019.10.008","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Desensitization to trimethoprim-sulfamethoxazole in a toxoplasmic encephalitis patient who was intolerant to conventional treatments","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2019.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}